Biogen BIIB
NASDAQ BIIB
$250.69 -3.15 (-1.24%)
At close: Oct 23, 2026 · 4:00 PM EDT

Biogen (BIIB) Net Income towards Common Stockholders (2009 - 2026)

Updated

Biogen (BIIB) recorded Net Income towards Common Stockholders of $97.5 million in Q2 2026, down 84.6% from $634.8 million a year earlier and down 69.5% from the prior quarter.

Analysis

Biogen (BIIB) Net Income towards Common Stockholders (2009 - 2026) Analysis & Trends

On a TTM basis, Biogen's Net Income towards Common Stockholders came in at $834.6 million as of Jun 30, 2026, down 45.5% year-over-year; for FY2025, it came in at $1.29 billion, down 20.8% from FY2024.

  • Annual Net Income towards Common Stockholders has a five-year compound annual growth rate of -20.2% (FY2020 to FY2025).
  • Across earlier years, Net Income towards Common Stockholders came in at $1.63 billion in FY2024 (+40.6%), $1.16 billion in FY2023 (-61.9%), $3.05 billion in FY2022 (+95.8%) and $1.56 billion in FY2021 (-61.1%).
  • Quarterly Net Income towards Common Stockholders has ranged from -$68.1 million in Q3 2023 to $1.13 billion in Q3 2022 over the past five years.
  • On a year-over-year basis, Net Income towards Common Stockholders rose in four of the last six quarters, with an average decline of 9.2%.
  • Peak year-over-year performance for Net Income towards Common Stockholders in the last five years was growth of 244.7% in Q3 2022, against a decline of 84.6% in Q2 2026 at the low end.
  • Per Business Quant, the preceding three quarters came in at $319.5 million (Q1 2026), -$48.9 million (Q4 2025) and $466.5 million (Q3 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Income (Qtr)
1 Eli Lilly 1,199.50 Bn 1,168.08 Bn 19.71 Bn 7.10 Bn
2 Johnson & Johnson 635.17 Bn 555.03 Bn 17.30 Bn 210.00 Mn
3 AbbVie 504.69 Bn 477.85 Bn 12.70 Bn 3.61 Bn
4 Merck 358.43 Bn 312.86 Bn 12.21 Bn -1.34 Bn
5 Novartis Ag 288.36 Bn 252.75 Bn 11.24 Bn 3.26 Bn
6 Astrazeneca 265.78 Bn 239.54 Bn 12.86 Bn 2.51 Bn
7 Amgen 237.46 Bn 192.86 Bn 7.24 Bn 2.38 Bn
8 Gilead Sciences 193.65 Bn 167.76 Bn 6.22 Bn -10.50 Bn
9 Pfizer 171.05 Bn 118.00 Bn 10.94 Bn -248.00 Mn
10 Biogen 37.04 Bn 23.70 Bn 1.96 Bn 97.50 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 97.50 Mn
Mar 31, 2026 319.50 Mn
Dec 31, 2025 -48.90 Mn
Sep 30, 2025 466.50 Mn
Jun 30, 2025 634.80 Mn
Mar 31, 2025 240.50 Mn
Dec 31, 2024 266.70 Mn
Sep 30, 2024 388.50 Mn
Jun 30, 2024 583.60 Mn
Mar 31, 2024 393.40 Mn
Dec 31, 2023 249.70 Mn
Sep 30, 2023 -68.10 Mn
Jun 30, 2023 591.60 Mn
Mar 31, 2023 387.90 Mn
Dec 31, 2022 550.40 Mn
Sep 30, 2022 1.13 Bn
Jun 30, 2022 1.06 Bn
Mar 31, 2022 303.80 Mn
Dec 31, 2021 368.20 Mn
Sep 30, 2021 329.20 Mn
API Access

Biogen Net Income towards Common Stockholders API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=net-income-towards-common-stockholders&ticker=BIIB&period=max&api_key=YOUR_API_KEY